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Abstract
Background: To study the methylation status of genes that play a role in the p53-Bax mitochondrial apoptosis
pathway and its clinical significance in cholangiocarcinoma.
Patients and Methods: Out of 36 cases cholangiocarcinoma patients from April 2000 to May 2005 were collected.
Promoter hypermethylation of DAPK, p14
ARF, and ASC were detected by methylation-specific PCR on
cholangiocarcinoma and normal adjacent tissues samples. Mutation of the p53 gene was examined by automated
sequencing. Correlation between methylation of these genes and/or p53 mutation status with clinical
characteristics of patients was investigated by statistical analysis.
Results: We found 66.7% of 36 cholangiocarcinoma patients had methylation of at least one of the tumor suppressor
genes analyzed. p53 gene mutation was found in 22 of 36 patients (61.1%). Combined p53 mutation and DAPK, p14
ARF,
and/or ASC methylation was detected in 14 cases (38.9%). There were statistically significant differences in the extent of
pathologic biology, differentiation, and invasion between patients with combined p53 mutation and DAPK, p14
ARF,a n d /
or ASC methylation compared to those without (P < 0.05). The survival rate of patients with combined DAPK, p14
ARF,
and ASC methylation and p53 mutation was poorer than other patients (P < 0.05).
Conclusion: Our study indicates that methylation of DAPK, p14
ARF, and ASC in cholangiocarcinoma is a common
event. Furthermore, p53 mutation combined with DAPK, p14
ARF, and/or ASC methylation correlates with malignancy
and poor prognosis.
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Background
Apoptosis or programmed cell death is a normal physiolo-
gical control mechanism that is critical in maintaining
homeostasis. Apoptotic inhibition can lead to abnormal
cell survival and carcinogenesis. The p53-Bax mitochon-
drial apoptosis pathway plays an important role in indu-
cing cell death after DNA damage or under conditions of
cellular stress [1]. However, some genes in the pathway
have latent methylation sites, such as p14
ARF, DAPK, and
ASC/TMS1, which can be methylated and inactivated
resulting in cancer development [2]. Studies investigating
methylation of gene that play a role in activation of the
p53-Bax mitochondrial apoptosis pathway has not been
well studied in cholangiocarcinoma to date. Thus, investi-
gation of the methylation status of the genes in this path-
way may give insight into the mechanism of
cholangiocarcinoma development, resulting in enhanced
diagnostic and treatment capabilities. We determined the
methylation status of p14
ARF, DAPK,a n dASC/TMS1 as
well as p53 mutation status in cancerous and normal adja-
cent tissue for 36 cholangiocarcinoma patients. Correla-
tion between p14
ARF, DAPK, and ASC/TMS1 methylation
and/or p53 mutation with the biological behavior of cho-
langiocarcinoma and clinical outcome was examined.
Methods
1. Patients
Cholangiocarcinoma and normal adjacent tissues sam-
ples were randomly selected from specimens obtained
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resection from April 2000 to May 2005 in the Depart-
ment of General Surgery of the First Affiliated Hospital
of China Medical University and Hepatobiliary Surgery
of the Affiliated Yantai Yuhuangding Hospital of Qing-
dao University Medical College. Informed consent was
obtained from all the patients. Samples included 18 tub-
ular adenocarcinomas, 9 papillary adenocarcinomas, 4
mucoid carcinomas, and 5 non-differentiated carcino-
mas. Twenty-five samples were well-moderately differen-
tiated and 11 samples were poorly differentiated.
According to the UICC standard, 16 cases were T1, 10
cases were T2, and 10 cases were T3. Lymph node
metastasis was found in 33 cases. Non-lymph node
metastasis was found in the 3 cases. This group con-
tained 23 males and 13 females, with ages ranging from
36 to 71 years (median age of 61.2 years). A11 of the
samples were frozen at -80°C until DNA extraction and
histological diagnosis by a pathologist.
2. DNA Extraction
DNA was obtained from samples using the QIAamp
DNA Micro kit according to the manufacturer’s instruc-
tions (Qiagen, Hilden, Germany). Briefly, tissue sample
weighing less than 10 mg was injected into a 1.5 ml
microcentrifuge tube, 180 μlB u f f e rA T La n d2 0μlp r o -
teinase k was immediately added followed by pulse-vor-
texing for 15 s. Samples were incubated overnight at 56°
C. Buffer AL (200 μl) and 100% ethanol (200 μl) were
added and samples incubated for 5 min at room tem-
perature. Lysate was then added to a QIAamp MinElute
Column, 500 μl Buffer AW1 and Buffer AW2 added,
and samples were centrifuged at 15000 rpm. Buffer AE
(100 μl) was added and DNA obtained. DNA was quan-
tified by spectrophotometric absorption and the A260/
280 ratio.
3. Methylation specific PCR
We examined the methylation status of genes by using
the methylation specific polymerase chain reaction
(MSP) method. Briefly, 1 mg of tissue DNA was urea/
bisulfite-treated to render unmethylated cytosines to ura-
cil according to the method previously described [3] to
render unmethylated cytosines to uracil. The modified
DNA was resuspended in 20 μl of TE Buffer and immedi-
ately subjected to PCR or stored at -20°C. Table 1 shows
primer sequences used for PCR. Primers were synthe-
sized by Hokkaido Bioscience Company (Ohtsu, Japan).
PCR reactions were performed with a 20 μl reaction
volume containing 1 U of Hot start EX Taq DNA poly-
merase (Takara Biochemical, Japan), 2 μl of 10X EXtaq
Buffer, 2 μlo fd N T Pm i x t u r e ,f o r w a r da n dr e v e r s ep r i -
mers (8 pmol each), and 1 μl of DNA template. The
conditions for the first PCR reaction were as follows:
96°C for 3 min, 40 cycles: 96°C for 30 s, 60°C for 30 s,
72°C for 30 s; 72°C for 4 min. Intergen (IVD) was used
as positive control for methylation. DNA from normal
lymphocytes was used as a negative control for methyla-
tion, and water was used as a negative control. PCR pro-
duct (5 μl) was resolved by 1.0% TBE gel
electrophoresis. Each MSP reaction was repeated at least
three times.
4. PCR amplification and DNA sequencing
Primers for amplification of p53 exon 5-8 were synthe-
sized by Hokkaido Bioscience Company(Japan)[4]. PCR
used a 20 μL reaction volume containing 1 unit of Hot
start EXTaq DNA polymerase (Takara, Biochemical,
Japan), 2 μLo f1 0×E X T a qB u f f e r , 2μLo fd N T Pm i x -
ture and each primers (8 pmol each for reaction)and 1
μL of DNA template. The condition of the first PCR
was as follows: 96°C 3 min for denaturation, 40 cycles of
PCR,(96°C,30s,60°C,30s,72°C,30s) with a final elongation
step of 4 min at 72°C.Water was used as negative con-
trol. PCR product (5 μl) was resolved by 10 g/L TBE gel
electrophoresis. Each PCR reaction was repeated three
times.
All of the PCR products were purified using Auto seq
TMG-50 (Amersham Biochemical Company, Piscataway,
NJ). BigDye Terminator Cycle sequencing Ready Reac-
tion (Perkin Elmer, Waltham, MA) was performed to
sequence DNA. The sequencing primers used were the
same as the PCR primers, but, the concentration was 1/
10th of that used for the PCR reaction. The sequencing
reaction condition was as follows: 95°C, 4 min; 40
cycles: 95°C for 30 s, 55°C for 30 s, 72°C for 30 s; 72°C
for 4 min. Both sense and antisense products were ana-
lyzed on an ABI prism 310 Genetic Analyzer (Perkin
Elmer). Each reaction was repeated three times.
Table 1 MSP primers sequences
gene primer sequences product
(bp)
p14
ARF M: GTG TTA AAG GGCTGGCCGTAGGC 122
AAA ACC CTC ACT CGC GAC GA
U: TTT TTG GTG TTA AAG GGT GGT GTA GT 132
CAC AAA AAC CCT CAC TCA CAA CAA
DAPK M: GGA TAG TCG GAT CGA GTT AAC GTC 98
CCC TCC CAA ACG CCG A
U: GGA GGA TAG TTG GAT TGA GTT AAT
GTT
106
CAA ATC CCT CCC AAA CAC CAA
TMS1/
ASC
M: TTG TAG CGG GGT GAG CGG C 191
AAC GTC CAT AAA CAA CGC G
U: GGT TGT AGT GGG GTG AGT GGT 196
CAA AAC ATC CAT AAA CAA CAA CAC A
M: Methylated specific PCR primers. U: Unmethylated specific PCR primers.
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A follow-up visit at the hospital was offered every three
months for the first year after surgery, every six months
for the second year, and every six to nine months for
the third year. All follow-up data was recorded.
6. Statistical analysis
A l ld a t aw e r ea n a l y z e db yC h i - s q u a r et e s to rS p e a r m a n
rank correlation analysis. The survival rate was calcu-
lated using the Kaplan-Meier method and compared
with long-rank test using SPSS 13.0 software (IBM,
Armonk, NY; size of test a = 0.05).
Results
1.p14
ARF, DAPK, and ASC/TMS1 methylation status in
cholangiocarcinoma
The methylation status of tumor suppressor genes that
play a role in the p53-Bax mitochondrial apoptosis path-
way (p14
ARF, DAPK, and TMS1/ASC) was investigated
in cholangiocarcinoma samples. It was found that 66.7
of 36 cases had methylation of at least one of these
genes. The frequency of methylation in cholangiocarci-
noma tissue was: p14
ARF (24.0%), DAPK (30.6%), and
TMS1/ASC (36.1%). The frequency of methylation in
normal adjacent tissue was low: DAPK (5.6%) and
TMS1/ASC (8.3%) (Figure 1). Methylation of all tumor
suppressor genes analyzed was significantly increased in
cholangiocarcinoma samples compared to normal adja-
cent tissue (P < 0.001).
2. p53 gene mutations in cholangiocarcinoma tissue
Exon 5-8 of p53 was amplified by PCR in all samples;
gene mutations were detected by DNA sequencing.
Mutations in p53 were detected in 22 of 36 patients
(61.1%). There were 7 cases of exon 5 mutations,
located on codons 161, 175 and 196 codon. All these
mutations were transitions (G:C/A:T). Exon 6 mutations
were detected in 6 cases, located on codons 209, 213,
and 215; 4 mutations were transitions (G:C/A:T) and 2
mutations were tranversions (G-T). Exon 7 mutations
were found in 3 cases, located on codons 248 and 252.
Exon 8 mutations were detected in 6 cases, located on
codons 282, 287, 289, and 306; 4 mutations were transi-
tions (G:C/A:T) and 2 mutations were tranversions (G-
T) (Figure 2, 3, and 4).
3. Methylation patterns of DAPK, p14
ARF, and ASC in
cholangiocarcinoma
Promoter region methylation of p14
ARF,D A P K ,a n d
TMS1/ASC in cholangiocarcinoma is common. There
were 15 cases (41.1%) with methylation of one of these
genes, 9 cases (25.0%) with methylation of two of these
genes, and no cases where all three genes were methy-
lated. In some cases (13.9%) of one of these genes was
found to be methylated in normal adjacent tissue, how-
ever, there were no cases where two of these genes were
found methylated in normal tissue. None of these genes
was found to be methylated at a significantly higher
level in tumor tissue than the other genes (P > 0.05).
The methylation profile for p14
ARF,D A P K ,a n dT M S 1 /
ASC in all 36 cases of cholangiocarcinoma examined is
summarized in Figure 5.
4. Correlation between p14
ARF, DAPK, and TMS1/ASC
methylation, p53 mutation, and pathologic biology in
cholangiocarcinoma
There were no statistically significant differences in age
or gender in the methylation of p14
ARF,D A P K ,a n d
TMS1/ASC or p53 gene mutation on p53-Bax mito-
chondrial apoptosis pathway. Combined p53 mutation
and p14
ARF, DAPK, and/or TMS1/ASC methylation was
found in 14 out of 36 cases (38.9%). Interestingly, p53
mutation and p14
ARF, DAPK, and/or TMS1/ASC methy-
lation was often found in mucoid carcinomas and non-
differentiated carcinomas, these tumors tended to be
poorly differentiated and had a deeper extent of inva-
sion. There was a correlation between the occurrence of
p53 mutations and tumor pathology, differentiation, and
invasion (P < 0.05) (Table 2). Although combined p53
gene mutation and p14
ARF, DAPK, and/or TMS1/ASC
methylation was often found in patients with lymph
node metastasis, this observation was not statistically
significant (P > 0.05).
5. Correlation of combined p14
ARF, DAPK, and TMS1/ASC
methylation and p53 mutation with prognosis in
cholangiocarcinoma
Complete follow-up information was available for all the
36 patients enrolled in this study with a mean follow-up
time period of 23.78 months, in which 29 patients died
and 7 survived. The one-, two-, and three-year survival
rates were 44.0%, 21.0%, and 14.0%, respectively, with a
median survival time of 22.29 months. The one-, two-,
Figure 1 Methylation specific PCR analysis of p14
ARF, TMS1/
ASC, and DAPK in cholangiocarcinoma and normal adjacent
tissue. L: 100 bp DNA ladder; U: unmethylated primers; M:
methylated primers;. a-e:cholangiocarcinoma samples; IVD: positive
control; N: negative control.
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methylation of p14
ARF,D A P K ,a n d / o rT M S 1 / A S Cand
p53 mutation was 28.0%, 5.0%, and 0.0%, respectively,
w i t ham e d i a ns u r v i v a lt i m eo f1 8 . 6m o n t h s .T h eo n e - ,
two-, and three-year survival rates of patients without
combined methylation of the tumor suppressor genes
analyzed was 70.0%, 43.0%, and 28.0%, with a median
survival time of 33.1 months. The survival rate between
Figure 2 Representative transition of p53 exon 5 (G: C/A: T) found in cholangiocarcinoma.
Figure 3 Representative transition of p53 exon 6 (G: C/A: T) found in cholangiocarcinoma.
Figure 4 Representative tranversion of p53 exon 8 (G ® T) found in cholangiocarcinoma.
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2 = 9.06, P <
0.05) (Figure 6). Combined p53 mutation and p14
ARF,
DAPK, and/or TMS1/ASC methylation correlated with
poor prognosis.
Discussion
Cholangiocarcinoma is a malignant tumor of the epithe-
lial bile duct, and accounts for 3.0% of malignant tumors
of the gastrointestinal tract [5,6]. In recent years, the
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Figure 5 Methylation profile of p14
ARF, TMS1/ASC,a n dDAPK and p53 mutation in cholangiocarcinoma. Open boxes denote no
detectable methylation or mutation. Shaded boxes represent positive methylation or mutation.
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due to this disease have been increasing [7,8]. The mean
age of patients with cholangiocarcinoma is 50 years, and
the incidence in males is 1.5 times greater than that in
females [9-11]. Without special clinical manifestations
and tumor markers, early diagnosis and treatment of
cholangiocarcinoma is very difficult.
Mammalian cells possess the capacity to epigenetically
modify their genomes via the covalent addition of a methyl
group to the 5-position of the cytosine ring within the
context of the CpG dinucleotide. Certain regions of the
genome, which are often clustered at the 5’-ends of genes
possess the expected CpG frequency and have been
termed CpG islands. CpG island methylation has been
shown to be essential for normal development, X-chromo-
some inactivation, imprinting, and the suppression of
parasitic DNA sequences. However, hypermethylation of
CpG islands can cause inactivation of genes [12,13].
In this study, promoter hypermethylation of DAPK,
p14
ARF,a n dASC was detected by methylation-specific
Table 2 Correlation between combined p53 mutation and p14
ARF, DAPK, and/or ASC/TMS1 methylation with pathologic
biology in cholangiocarcinoma
combined p53 mutation and p14
ARF, DAPK, and/or ASC/TMS1 methylation
Pathologic character cases positive positive ratio (%) P-value
Pathologic type
Tubular carcinoma 18 5 27.8
Papillary carcinoma 9 1 11.1
Mucoid carcinoma 4 4 100.0
Non-differentiated 5 4 80.0 < 0.05
carcinoma
Differentiation
Well -Moderate 25 6 24.0
Poor 11 8 72.7 < 0.05
Invasion
T1 16 2 12.5
T2 10 4 40.0
T3 10 8 80.0 < 0.05
Lymph node metastasis
N0 3 0 0
N1 33 14 42.4 > 0.05
Figure 6 Kaplan-Meier curve of p14
ARF, TMS1/ASC,a n dDAPK methylation and p53 mutation on p53-Bax mitochondrial apoptosis
pathway and prognosis in cholangiocarcinoma. Positive: patients with combined p53 mutation and p14
ARF, TMS1/ASC, and/or DAPK; negative:
patients without combined p53 mutation and p14
ARF, TMS1/ASC, and/or DAPK; + = a patient death.
Xiaofang et al. World Journal of Surgical Oncology 2012, 10:5
http://www.wjso.com/content/10/1/5
Page 6 of 8PCR, and mutation of the p53 gene status at exons 5-8
was examined by automated sequencing in 36 cases of
cholangiocarcinoma. We found that 66.7% of patients
had methylation of at least one of the tumor suppressor
genes analyzed. The frequency of methylation in cholan-
giocarcinoma was: p14
ARF (24.0%), DAPK (30.6%), and
TMS1/ASC (36.1%). The frequency of methylation in
normal adjacent tissues was: DAPK (5.6%) and TMS1/
ASC (8.3%). p53 gene mutations were found in 22 of 36
patients (61.1%). Combined p53 mutation and DAPK,
p14
ARF,a n d / o rASC methylation was detected in 14
cases (38.9%).
The p53-Bax mitochondrial apoptosis pathway plays
an important anti-tumor role. When cells suffer DNA
damage or certain types of stress, p53 is activated and
sends a death signal to cells. p53 activity is regulated by
MDM2, which induces the degradation of p53. MDM2
levels are regulated by p14
ARF. DNA damage or cellular
stress induces expression of p14
ARF, resulting in degra-
dation of MDM2 and stabilization of p53. Stress signals
induce p14
ARF expression, in part, through death-asso-
ciated protein kinase, DAPK. Activated p53 promotes
apoptosis through Bax, a molecule that stimulates the
release of cytochrome-c from mitochondria, activating
procaspase-9 and resulting in cell death. TMS1/ASC
plays a role in caspase-9-mediated apoptosis. Expression
of regulators of the p53-Bax mitochondrial apoptosis
pathway, including p14
ARF, DAPK, and ASC/TMS1, can
become inactivated by promoter methylation and lead
to the destruction of the pathway [14,15]. Our study
indicates that methylation of regulators of the p53-Bax
mitochondrial apoptosis pathway is a common epige-
netic event in cholangiocarcinoma.
Futhermore, we found p53 gene mutation combined
with DAPK, p14
ARF, and/or ASC methylation in 14 cases
(38.9%), which correlated with extent of pathologic biol-
ogy, differentiation, and invasion of the tumors (P <
0.05). Patients with combined p53 mutation and methy-
lation of tumor suppressor genes tended to have more
malignant tumors. Moreover, the one-, two-, and three-
year survival rate of patients with combined tumor sup-
pressor gene methylation and p53 mutation was 28.0%,
5.0%, and 0.0%, respectively, with a median survival time
of 18.6 months. Those patients without combined p53
mutation and tumor suppressor methylation was 70.0%,
43.0%, and 28.0%, with a median survival of 33.1
months. Therefore, combined p53 mutation and DAPK,
p14
ARF,a n d / o rASC methylation correlates with poor
prognosis in cholangiocarcinoma patients.
Although surgery can relieve obstruction of the biliary
tract, the distinct pathobiology of cholangiocarcinoma
makes it difficult to obtain a radical surgical cure. Thus,
chemotherapeutics are an important part of combined
therapy. However, at present, it is unclear how effective
chemotherapeutics are in treating cholangiocarcinoma
patients. Our study indicates the methylation status of
regulators of the p53-Bax mitochondrial apoptosis path-
way could indicate the biological behavior of cholangio-
carcinoma and predict prognosis of these patients,
providing a basis for postoperative adjunctive treatment
[16]. Further research is needed to investigate the
methylation status of p53-Bax mitochondrial apoptosis
pathway genes in cholangiocarcinoma patients and how
this correlates with response to drug therapy.
Conclusion
In conclusion, 66.7% of 36 cholangiocarcinoma cases
had methylation of at least one of the tumor suppressor
genes analyzed. These data indicate that methylation of
genes that regulate the p53-Bax mitochondrial apoptosis
pathway is a common event cholangiocarcinoma. Muta-
tion of the p53 gene was found in 61.1% of cases. Com-
bined p53 mutation and DAPK, p14
ARF,a n d / o rASC
methylation was found in 38.9% of cases, and these
patients had a poorer pathologic biology and prognosis
than the other patients. Future studies are required to
assess DAPK, p14
ARF,a n dASC methylation status and
to the possibility of using DNA demethylating drugs to
treat cholangiocarcinoma patients.
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